{"id":"W3212987218","doi":"10.1016/j.ejca.2021.10.015","title":"Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region","year":2021,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Foundation Medicine; Sanofi Genzyme; Cilag; Astellas Pharma; Genentech; UroGen Pharma; Boston Scientific Corporation; Array BioPharma; Invitae; Gilead Sciences; Daiichi Sankyo Europe; Sanofi; Bristol-Myers Squibb; AstraZeneca; Astellas Foundation for Research on Metabolic Disorders; Amgen; Pfizer; Daiichi Sankyo Company; Ipsen; Clovis Oncology; Astellas Pharma US","keywords":"Enzalutamide; Medicine; Prostate cancer; Androgen deprivation therapy; Placebo; Internal medicine; Oncology; Adverse effect; Post-hoc analysis; Subgroup analysis; Multivariate analysis; Cancer; Androgen receptor; Confidence interval; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004548736,0.0001512731,0.0005024032,0.0001970104,0.00004447457,0.0000384639,0.00006097204,0.00001807356,0.00005198599],"category_scores_gemma":[0.000018101,0.0001020269,0.00009295434,0.0005908653,0.0001125874,0.0001247515,0.00001915006,0.0001719498,2.380971e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002488151,"about_ca_system_score_gemma":0.0004238919,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002301858,"about_ca_topic_score_gemma":0.001242488,"domain_scores_codex":[0.9983733,0.0002005596,0.0005234539,0.0002107609,0.0004957007,0.0001962111],"domain_scores_gemma":[0.998836,0.00004257685,0.0003860792,0.0001526561,0.0004517597,0.0001309583],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01675487,0.0003458472,0.8392009,0.0002643243,0.004373453,0.00651471,0.004220195,0.00181493,0.08997327,0.00003367711,0.0003470763,0.03615678],"study_design_scores_gemma":[0.01866367,0.003145448,0.9221655,0.0008593612,0.001427969,0.0001431597,0.001224189,0.0002699964,0.05017628,0.00002482099,0.001629072,0.0002706074],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9757797,0.02220543,0.00006053353,0.001120422,0.0000296364,0.0003211976,0.00004286509,0.000003818303,0.0004364672],"genre_scores_gemma":[0.979705,0.01875374,0.0002700409,0.00006176515,0.00004416984,0.00001264271,0.0000311255,0.0000258508,0.001095628],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.08296456,"threshold_uncertainty_score":0.4160535,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03063415493813856,"score_gpt":0.2966533057847531,"score_spread":0.2660191508466146,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}